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Introduction
The strategy of the World Health Organization is to de-
velop efficient and inexpensive vaccines against various 
diseases. Traditionally, adjuvants have been used in vac-
cine formulations to augment the immune response, usu-
ally after a booster dose. Hepatitis B is an acute systemic 
infection, which constitutes a major health problem 
all over the world. The risk of infection may vary from 
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BACKGROUND/PURPOSE: The purpose of this research was to develop an alternative adjuvant for 
hepatitis B vaccine (HBsAg) that elicits a long-lasting immune response after a single administration. In 
this study, the suitability of Poly (D, L)-lactide-co-glycolic acid (PLGA), Poly lactic acid (PLA) and Chitosan 
polymers as adjuvants for HBsAg were investigated.
METHODS: We used solvent evaporation and emulsion cross-linking techniques to encapsulate HBsAg 
into the different polymeric systems. The newly developed microparticles were evaluated for vaccine con-
tent, particle size distribution, in vitro release and immunogenicity.
RESULTS: HBsAg-encapsulated PLGA and PLA microparticles were smooth and spherical. However, 
Chitosan microparticles were homogeneous, and almost spherical, with rough surfaces. The vaccine load-
ing and release patterns varied with the type of polymer used. In this study, Chitosan polymeric micropar-
ticles released antigen until day 63 post-injection; however, the release period of the PLGA and PLA 
systems was shorter. A significant increase in the level of antibodies to HBsAg was induced by all the
polymeric microparticles.
CONCLUSION: The results indicate that Chitosan microparticles are a more efficient adjuvant for 
HBsAg than PLGA and PLA polymeric microparticles.
KEYWORDS: adjuvant, biodegradable polymers, hepatitis B vaccine, vaccine delivery system
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country to country. Approximately, 30% of world’s popu-
lation has serological evidence of hepatitis B infection.1 
Hepatitis B virus infection can lead to fulminant hepatic 
failure that threatens the life of affected patients.2 A safe 
and effective vaccine against the hepatitis B virus has been 
available for nearly 20 years; however, it requires that at 
least three doses be administered at the appropriate time 
intervals soon after birth to elicit optimum immune 
responses. Currently, alum is the only adjuvant approved 
for human use and plays a major role in vaccine delivery, 
but alum is not a universal adjuvant because it is not suit-
able for small peptides. Furthermore, alum-type adjuvants 
induce cell-mediated immunity. The Global Alliance for 
Vaccine Initiative has suggested the use of a combined 
diphtheria-hepatitis B vaccine as a more efficient method 
of pediatric vaccine delivery. Unfortunately, the cost per 
dose of this combined vaccine is significantly higher than 
the separate diphtheria and hepatitis B vaccines.3 More-
over, as diphtheria cannot be given before 6 weeks of age 
due to deprived immunogenicity, the combined diphtheria-
hepatitis B vaccine cannot be given before 6 weeks of age 
either. Thus it is necessary to find an alternative adjuvant 
that elicits a long-lasting immune response after a single 
dose. Biode gradable polymers have been used as sutures 
and drug carriers because of their nontoxic nature and 
their adjustable biodegradable properties. Polymers chosen 
for parenteral administration should meet some of the 
requirements, e.g. being biodegradable, safe, drug com-
patible and permeable, stable in vitro, easy to process and 
inexpensive.
Biodegradable synthetic and natural polymers have 
been investigated for the controlled release of vaccines and 
drugs. Polymers in the form of microparticles are pre-
ferred for the controlled delivery of vaccines, which mim-
ics both the primary and boosting dose of a conventional 
vaccine. Moreover, microspheres are also capable of pro-
tecting antigens from rapid destruction in vivo, allowing 
presentation of antigen in its native confirmation to various 
cells of the immune system.4 The ability of future vaccines 
to provide maximum efficacy after a minimum dose is 
delivered safely and easily is of prime importance.5 Based 
on these factors, the development of a single administra-
tion hepatitis B vaccine using a biodegradable polymeric 
system is an important advancement towards the better-
ment of human health care.
Methods
Materials
Poly (D, L)-lactide-co-glycolide acid (PLGA), with a lactide/
glycolide ratio of 50/50 (MW = 50 kDa), and Poly lactic 
acid (PLA, MW = 2 kDa) polymers were purchased from 
Sigma Aldrich (St. Louis, MO, USA). Chitosan polymer 
(150 cps viscosity grade) and hepatitis B vaccine (alum-
free HBsAg, 3 mg/mL solution) were provided by the 
Central Institute of Fisheries Technology, Cochin, India 
and Serum Institute of India, Pune, India, respectively. 
Extensive pre-formulation studies were carried out in 
order to encapsulate hepatitis B vaccine in the polymeric 
microparticles.
Preparation of hepatitis B vaccine-encapsulated 
PLGA/PLA microparticles
Briefly, PLGA or PLA polymer solutions were prepared by 
dissolving 100 mg of polymer in 1 mL of methylene chlo-
ride followed by emulsification with 200 μL of alum-free 
HBsAg aqueous solution (3 mg/mL) using a cyclomixer 
for 1 minute. The emulsion was sonicated at 15,000 rpm, 
dispersed in 2% w/v polyvinyl alcohol (PVA) solution and 
stirred for 6 hours to allow solvent evaporation. The re-
sulting microparticles were collected by centrifugation at 
10,000 ×g and were washed three times with phosphate 
buffered saline solution (pH 7.4) to remove free HBsAg. 
The collected microparticles were suspended in 50 mL 
of distilled water and immediately filtered through a 
membrane filter and dried in a vacuum desiccator.
Preparation of hepatitis B vaccine-encapsulated 
Chitosan microparticles
Briefly, 1% w/v solution of Chitosan (medium molecular 
weight with 75–85% deacetylation, 150 cps viscosity grade) 
was prepared in aqueous acetic acid (5% v/v). The solution 
was mixed with an emulsion containing sunflower oil, or 
liquid paraffin, to form a water-in-oil emulsion. To this 
emulsion, 1 mL of alum-free HBsAg aqueous solution 
(3 mg/mL) was added and stirred for half an hour. Finally, 
1 mL of glutaraldehyde was added and the emulsion was 
stirred at 3,000 rpm for 1 hour. The emulsion was centri-
fuged at 15,000 rpm and the oil layer was removed. The 
remaining pellet was washed with organic solvents in order 
to remove excess oil. The collected microparticles were 
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suspended in 50 mL of distilled water and immediately 
filtered through a membrane filter and dried in a vacuum 
desiccator.
Physicochemical characterization
The morphological examination of microparticles was per-
formed by scanning electron microscopy (SEM; JSM–T220, 
JEOL, Japan). Samples used for SEM were mounted on to 
metal stubs and coated with gold palladium to a thickness 
of 200–300 Å under reduced pressure. The size of the mi-
croparticles was determined using a microscope (Olympus 
BX 50, Tokyo, Japan) in which 100 particles were counted 
to calculate the average diameter. The magnitude of vaccine 
loading in the microparticles was determined by a previ-
ously established method with a slight modification.6 The 
amount of HBsAg loaded into the PLGA and PLA micro-
particles was determined by dissolving 50 mg of micropar-
ticles in 1 mL of a 0.1 M NaOH/5% sodium dodecyl sulfate 
solution. The supernatant was centrifuged and analyzed 
for protein content using Lowry’s method.7 The stability 
of the vaccine-loaded and -unloaded PLGA microspheres 
was determined over a period of 8 weeks. The microspheres 
were exposed at 4ºC, at room temperature, and at 50ºC.
In vitro release study
Hepatitis B vaccine-encapsulated microparticles (100 mg) 
were suspended in 50 mL of phosphate buffer saline 
(154 mM, pH 7.4) containing Tween 80. The flask was 
then kept in shaker/incubator. At predetermined time in-
tervals (Days 1, 2, 4, 7, 10, 14, 21, 28, 35, 42, 49, 56, 63 and 
70) the antigenically active vaccine was analyzed by Enzyme 
Immune Assay for HBsAg (Diagnostic Products Corpora-
tion, Los Angeles, CA, USA). The quantity of HBsAg in the 
samples was calculated by comparing the standard curves.
Immunogenicity studies
Immunogenicity studies were carried out on healthy Wistar 
rats, weighing about 150–250 g. The animals were main-
tained and handled according to the standard guidelines 
of Institutional Animal Ethical Committee 290/CPCSEA/
2006. The animals were divided into four groups and each 
group contains 6 rats. All the animals were injected intra-
muscularly at the thigh region with a quantity of 0.5 mL 
of vaccine formulation (2 μg i.e. one-tenth of the standard 
human dose). The various treatment groups are: Group 1, 
animals received hepatitis B vaccine-encapsulated Poly 
(D,L)-lactide-co-glycolic acid microspheres; Group 2, 
animals received hepatitis B vaccine-encapsulated PLA 
microspheres; Group 3, animals received hepatitis B 
vaccine-encapsulated Chitosan microspheres; and Group 4, 
animals received conventional alum-adsorbed hepatitis B 
vaccine. Blood samples were collected from the retro-
orbital plexus using a capillary tube on Days 45 and 
90. Sera were separated by centrifugation and stored at 
−20ºC until assayed. The immunopotentiation was deter-
mined by measuring specific anti-hepatitis B antibodies 
using an enzyme-linked immunoabsorbent assay and an 
Immulite 2000 automated analyzer (Diagnostic Products 
Corporation). The immunoglobulin titers were measured 
using IgG and IgM assay kits (Turbox, Orion Diagnostica, 
Finland).
Results
Physicochemical characterization
The effect of two different concentrations of PVA on micro-
particle size, loading and stability are shown in Table 1. 
In both the PLGA and PLA polymer systems, the size of 
the microparticles were reduced, and the encapsulation 
Table 1. Effect of two different concentrations of polyvinyl alcohol on microparticle formation
Polymeric PVA Microparticle Loading of vaccine  Microparticle stability at 8 wk
system concentrations (% w/v) size (μm) in microparticles (%) 4ºC Room temperature 50ºC
PLGA 1.5 124.1 ± 2.10 26.0 ± 5.3 Stable Less stable Not stable
 2.0 122.1 ± 1.60 30.0 ± 2.1 Stable Stable Not stable
PLA 1.5 127.5 ± 2.60 18.3 ± 2.8 Stable Less stable Not stable
 2.0  94.0 ± 1.90 36.1 ± 1.3 Stable Stable Not stable
PVA = Polyvinyl alcohol; PLA = Poly lactic acid; PLGA = Poly (D,L)-lactide-co-glycolic acid.
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efficiency and stability was increased when 2% w/v of PVA 
was used as the external phase. For the Chitosan polymer 
system, two different oil phases were used as the continu-
ous phase to formulate the water-in-oil emulsion. The oil 
phases used were sunflower oil and liquid paraffin. The 
effect of the oil phases was determined in terms of micro-
particle size, vaccine loading and stability. It was clear that 
improved stability, loading and reduced micro-particle 
size were achieved when sunflower oil was used as the 
external phase (Table 2). The HBsAg-encapsulated PLGA 
and PLA microparticles, which prepared using the solvent 
evaporation method, were spherical with a smooth surface; 
however, the Chitosan microparticles had a rough surface 
and a more-or-less spherical shape.
In vitro release study
HBsAg release may be due to the degradation of the poly-
mer latex leading to a swollen inner structure. A biphasic 
HBsAg release pattern was displayed in all the three mi-
croparticle system. Approximately 8–10% of encapsulated 
antigen was released from PLGA and PLA microparticles 
in the first 24 hours. Similarly, Chitosan microparticles 
also characterized by releasing 7–9% of antigen with in the 
first day of incubation. The amount of antigen released 
was significantly higher in the PLGA and PLA polymeric 
system during the first 4 days when compared to Chitosan 
polymeric microparticles. This may be due to various 
factors including surface morphology, particle size, viscos-
ity grade, polymer composition and polymer molecular 
weight.
Immunogenicity studies
The results shown in Table 3 represent comparative stud-
ies of specific immunoglobulin levels on Days 45 and 
90 (IgG, IgA and IgM). Dunnett’s test was used to com-
pare the immunoglobulin levels of the animals among 
different groups. The anti-HBsAg and immunoglobulin 
titers after immunization with HBsAg-loaded PLGA/PLA 
microparticles showed similar values on Days 45 and 90 
compared with the conventional alum-adsorbed vaccine 
(group 4). This suggests that both the PLGA and PLA poly-
mer microparticles elicited immune responses similar to 
Table 2. Effect of two oil phases on Chitosan polymeric system
 Microparticle stability at 8 wk
Polymeric 
Oil phases 
Microparticle Loading of vaccine 
 
4°C
 Room 
50°Csystem  size (μm) in microparticles (%)
  temperature
Chitosan Sunflower 36.0 ± 2.6 38.0 ± 1.2 Stable Stable Not stable
 Liquid paraffin 88.0 ± 1.2 26.0 ± 2.6 Stable Stable Not stable
Table 3. Comparative immunogenicity studya
 Anti-hepatitis B 
IgG (mg/dL) IgA (mg/dL) IgM (mg/dL)
Groupb antibody (IU/L)
 Day 45 Day 90 Day 45 Day 90 Day 45 Day 90 Day 45 Day 90
1 10.2 ± 0.6 11.3 ± 0.3 793.6 ± 2.4 791.3 ± 1.3 77.8 ± 2.3 78.8 ± 2.6 85.0 ± 1.2 85.3 ± 1.8
2 10.1 ± 0.2 11.2 ± 0.1 793 ± 1.7 789.6 ± 2.3 75.1 ± 1.7 77.3 ± 2.1 80.0 ± 1.6 85.3 ± 1.4
3 11.8 ± 0.1 12.4 ± 0.1 805.3 ± 4.8 809.0 ± 3.5 83.0 ± 1.4 80.6 ± 2.4 81.6 ± 2.0 85.3 ± 1.4
4 10.1 ± 0.6 10.9 ± 1.3  793.6 ± 1.7 789.6 ± 2.3 75.1 ± 1.7 77.3 ± 2.1 80.0 ± 1.6 85.3 ± 1.4
aData presented as mean ± standard deviation (n = 6; p ≤ 0.001; Dunnet multiple comparison test); bgroup 1 = animals received hepatitis B 
vaccine-encapsulated Poly (D,L)-lactide-co-glycolic acid microspheres, group 2 = animals received hepatitis B vaccine-encapsulated Poly lactic 
acid microspheres, group 3 = animals received hepatitis B vaccine-encapsulated Chitosan microspheres, group 4 = animals received conven-
tional alum-adsorbed hepatitis B vaccine.
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the conventional alum-adsorbed HBsAg. However, after a 
single-step immunization, the Chitosan microparticles 
(group 3) induced significantly higher immunoglobulin 
levels compared with the conventional alum-adsorbed 
(group 4), PLGA and PLA polymer microparticle systems 
(groups 1 and 2) up to Day 90 (Figure). These results show 
that the Chitosan microparticle system is a better adju-
vant than either the PLGA or PLA systems.
Discussion
Vaccines are considered as the most successful medical in-
terventions against infectious diseases. The development 
of new, more efficacious and easier to deliver vaccines has 
become an area of research that can certainly benefit from 
recent controlled release technology. In particular, the con-
version of multiple dose vaccines into single dose vaccines 
represents an important advancement towards the better-
ment of human health care. Injectable biodegradable poly-
meric microparticles represent an exciting approach to 
control the release of vaccine, reduce the number of doses, 
and optimize the desired immune response. Microparticulate 
vaccine antigens can mimic the priming and boosting 
doses of vaccines.8–11 Designing an effective vaccine against 
a particular pathogen involves certain key factors that tar-
get and trigger the immune response. Thus, the inclusion 
of “immunopotentiators”, i.e. adjuvants that trigger early 
innate immune responses to aid in the generation of a 
robust and long-lasting adaptive immune response, is ther-
apeutically very important. Therefore, adjuvants have tra-
ditionally been used in vaccine formulations to improve 
efficacy. The development of vaccine delivery systems 
prepared from biodegradable polymers has received con-
siderable attention over the past two decades. Several re-
search reports prove that polymeric microspheres can be 
considered as the next generation of adjuvants to replace 
aluminum salts for vaccine potentiation.12 Vaccine research 
is often focused on the identification and application of 
novel antigens. The immune response to these antigens is 
routinely optimized by assessing the dose and the number 
of injections. Owing to advances in biotechnology, many 
vaccines are poorly immunogenic, and therefore require 
several boosters with a standard adjuvant. Currently, 
alum is the only adjuvant that is approved for clinical use. 
The use of alum-type adjuvants for immunization, how-
ever, has several disadvantages. They induce inflamma-
tion and stimulate the local production of granulomas. 
In addition, alum is not a universal adjuvant as it is not 
suitable for small peptides or recombinant proteins and 
cannot be frozen or lyophilized. Conventional alum-type 
vaccines require multiple recall injections at appropriately 
timed intervals in order to achieve long-lasting and optimal 
immune responses. However, it is very difficult, especially in 
developing countries, to maintain a high re-immunization 
rate in the case of multiple-administration immunization 
programs. Therefore, the development of more efficient 
and safe adjuvant/vaccine delivery systems, requiring only 
a single administration to obtain high and long lasting 
immune responses, is of primary importance.
In this study, our objective was to evaluate the suitabil-
ity and potential of PLGA, PLA and Chitosan polymeric 
systems as adjuvants for hepatitis B vaccines that are easy 
to deliver and elicit a long-lasting immune response. Pre-
formulation studies were performed to ascertain the vari-
ables of microparticle formation. The continuous phase 
was selected based on the polymers and techniques em-
ployed to formulate the microparticles. An external phase 
containing PVA is known to be a key factor that influ-
ences the size of polyester polymeric microparticles. The 
concentration of PVA influences both the formation and 
size of the microspheres. During the solvent evaporation 
process, there was a gradual decrease in the volume of PVA, 
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Figure. Anti-hepatitis B antibody titers on Days 45 and 90 post-
vaccination. Group 1 = animals received hepatitis B vaccine-
encapsulated Poly (D,L)-lactide-co-glycolic acid microspheres; 
Group 2 = animals received hepatitis B vaccine-encapsulated Poly 
lactic acid microspheres; Group 3 = animals received hepatitis B 
vaccine-encapsulated Chitosan microspheres, Group 4 = animals 
received conventional alum-adsorbed hepatitis B vaccine.
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which leads to an increase in viscosity and particle aggre-
gation. Therefore, larger amount of PVA were used dur-
ing the micro-encapsulation process. Generally, the size 
of the microspheres dictates the length of the immune re-
sponse. Larger microspheres have slower release rates and 
longer periods of immunogenicity.13 Earlier reports have 
shown that the size of the microparticles influences the re-
lease rate of the antigen. It has been estimated that PLGA 
microparticles with particle sizes of 20–35 μm released 
about 50–90% of tetanus toxoid within the 1st day.14 Simi-
lar types of antigen release were observed in our study to 
those in a report by Sanchez et al,6 but the size of our PLGA 
and PLA polymeric microparticles are larger. In our study 
the size of PLGA and PLA microspheres was 120–126 μm 
(Table 1) displayed an initial burst release of 8–10% of 
encapsulated antigen. Almost 60% of antigen release was 
observed in both PLGA and PLA polymeric microspheres 
during the first 4 day of incubation. But the size of 
Chitosan microparticles was 36–39 μm displayed an intial 
burst release of 7–9% of antigen within 24 hours and sus-
tained release was observed until 63rd day. This suggests 
that Chitosan microparticles are a better adjuvant than 
PLGA or PLA. We also undertook a comparative study 
of anti hepatitis B antibodies and immunoglobulin titers 
on Days 45 and 90 (Table 3). The required level of anti-
hepatitis B antibodies to confer protection after vaccina-
tion is 10 IU/L. There fore, it is clear that all three polymeric 
microparticulate systems provide the minimum protection 
level. However, Chitosan induced a better immune response, 
even on Day 90. In contrast with an earlier report,11 our 
study proves that the entire immune system actively partic-
ipated in the production of acquired immunity against the 
microparticles after a single-step immunization, especially 
when Chitosan microparticles were used.
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